LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis

作者：Ma Shi Dong; Xu Xuequn; Plowshay Julie; Ranheim Erik A; Burlingham William J; Jensen Jeffrey L; Asimakopoulos Fotis; Tang Weihua; Gulley Margaret L; Cesarman Ethel; Gumperz Jenny E; Kenney Shannon C^*

来源：Journal of Clinical Investigation, 2015, 125(1): 304-315.

DOI：10.1172/JCI76357

Epstein-Barr virus (EBV) infection transforms B cells in vitro and is associated with human B cell lymphomas. The major EBV oncoprotein, latent membrane protein 1 (LMP1), mimics constitutively active CD40 and is essential for outgrowth of EBV-transformed B cells in vitro; however, EBV-positive diffuse large B cell lymphomas and Burkitt lymphomas often express little or no LMP1. Thus, EBV may contribute to the development and maintenance of human lymphomas even in the absence of LMP1. Here, we found that i.p. injection of human cord blood mononuclear cells infected with a LMP1-deficient EBV into immunodeficient mice induces B cell lymphomas. In this model, lymphoma development required the presence of CD4(+)T cells in cord blood and was inhibited by CD40-blocking Abs. In contrast, LMP1-deficient EBV established persistent latency but did not induce lymphomas when directly injected into mice engrafted with human fetal CD34(+) cells and human thymus. WT EBV induced lymphomas in both Mouse models and did not require coinjected T cells in the cord blood model. Together, these results demonstrate that LMP1 is not essential for EBV-induced lymphomas in vivo and suggest that T cells supply signals that substitute for LMP1 in EBV-positive B cell lymphomagenesis.

• 出版日期2015-1
• 单位河北医科大学